The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review
Abstract
Background Selective serotonin-reuptake inhibitors (SSRIs) are increasingly being used as first-line therapy for severe premenstrual syndrome (PMS). We undertook a meta-analysis on the efficacy of SSRIs in this disorder.Methods We searched medical and scientific databases, approached pharmaceutical companies, and reviewed citations of relevant articles to identify 29 studies of the use of SSRIs in PMS. 14 were excluded (no placebo group, preliminary report of included trial, or low quality). 15 randomised placebo-controlled trials were included. Information on study design, participants, drugs used and dosing regimens, outcome measures, side-effects, and sources of funding was extracted. Standardised mean differences between treatment and placebo groups were calculated to obtain an overall estimate of efficacy. The primary outcome measure was a reduction in overall PMS symptoms.Findings The primary analysis included data on 904 women (570 assigned active treatment and 435 assigned placebo, including 101 in crossover trials). The overall standardised mean difference was -1.066 (95% CI -1.381 to -0.750), which corresponds to an odds ratio of 6.91 (3.90 to 12.2) in favour of SSRIs. SSRIs were effective in treating physical and behavioural symptoms. There was no significant difference in symptom reduction between continuous and intermittent dosing or between trials funded by pharmaceutical companies and those independently funded. Withdrawal due to side-effects was 2.5 times more likely in the active-treatment group than in the placebo group.Interpretation SSRIs are an effective first-line therapy for severe PMS. The safety of these drugs has been demonstrated in trials of affective disorder, and the side-effects at low doses are generally acceptable.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The SSRIs fluoxetine, paroxetine, sertraline, escitalopram, and citalopram have been proven to reduce several premenstrual syndrome symptoms, although in some cases, side effects have also been reported with a dose-depended relationship [48,49].”
From Antimicrobial Properties of Antidepressants and Antipsychotics—Possibilities and Implications (2021) · cites this paper as [48]
In the citing paper
“Indeed, in these patients during the cure, no recurrent episodes of yeast infection were reported [48,50].”
From Antimicrobial Properties of Antidepressants and Antipsychotics—Possibilities and Implications (2021) · cites this paper as [48]
In the citing paper
“Interestingly, sertraline had also positive effects in women suffering from premenstrual syndrome and recurrent vulvovaginal candidiasis.”
From Antimicrobial Properties of Antidepressants and Antipsychotics—Possibilities and Implications (2021) · cites this paper as [48]
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Wasserman, S. S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,377
Statistical Methods for Meta-Analysis.
Freeman, P. R., Hedges, L. V., & Olkin, I. (1986) · Biometrics · doi:10.2307/2531069 · Cited by 4,840
Greene, R., & Dalton, K. (1953) · BMJ · doi:10.1136/bmj.1.4818.1007 · Cited by 1,819
Meta-analysis of screening and diagnostic tests.
Hasselblad, V., & Hedges, L. V. (1995) · Psychological Bulletin · doi:10.1037/0033-2909.117.1.167 · Cited by 579
Fluoxetine in the Treatment of Premenstrual Dysphoria
Steiner, M. S., Steinberg, S. I., Stewart, D. E., Carter, D., Berger, C., Reid, R. L., Grover, D., & Streiner, D. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506083322301 · Cited by 450
Progesterone metabolite allopregnanolone in women with premenstrual syndrome
RAPKIN, A., MORGAN, M., GOLDMAN, L., BRANN, D., SIMONE, D., & MAHESH, V (1997) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(97)00417-1 · Cited by 376
Research works printed but not linked: 1
- Rickels, 1990, Fluoxetine in the treatment of premenstrual syundrome, Curr Ther Res, 48, 161
Cited by
Sorted by citations
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 978
Barth, C., Villringer, A., & Sacher, J. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00037 · Cited by 779
“Thus, a better understanding of the interaction between sex hormones and dopaminergic neurotransmission could help to improve pharmacological treatment regimens for these diseases and significantly impact women’s mental health.”
BackgroundThe premenstrual symptoms screening tool (PSST) for clinicians
Steiner, M., Macdougall, M., & Brown, E. (2003) · Archives of Women's Mental Health · doi:10.1007/s00737-003-0018-4 · Cited by 641
“Prospective daily charting has been used primarily in PMS=PMDD randomized clinical trials (Sundblad et al., 1993; Steiner et al., 1995; Yonkers et al., 1997; Wikander et al., 1998; Freeman et al., 1999; Pearlstein et al., 2000; Dimmock et al., 2000; Halbreich et al., 2002; Cohen et al., 2002).”
BackgroundMethodNeurosteroids: biochemistry and clinical significance
Mellon, S. H., & Griffin, L. D. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00503-3 · Cited by 538
Circadian rhythms, sleep, and the menstrual cycle
Baker, F. C., & Driver, H. S. (2007) · Sleep Medicine · doi:10.1016/j.sleep.2006.09.011 · Cited by 529
“The accompanying mood instability during the hypoestrogenic periods may be modulated by a variety of neurotransmitter systems including serotonergic, opiodergic, GABAergic, adrenergic and cholinergic [67–69], and is reportedly relieved by selective serotonin reuptake inhibitors [67,68,70].”
Background
Metadata
- Authors
- Dimmock, P. W., Wyatt, K. M., Jones, P. W., & O'Brien, P. S.
- Affiliations
- University Hospitals of North Midlands NHS Trust (GB)
- Keele University (GB)
- Corresponding author
- Dimmock, Paul W
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2000-09
- Volume
- 356
- Issue
- 9236
- Pages
- 1131-1136
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2119435034
- Cited by
- 368
- References
- 47
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 6 · 2023: 10 · 2022: 11 · 2021: 4 · 2020: 4 · 2019: 7 · 2018: 9 · 2017: 11 · 2016: 16 · 2015: 14 · 2014: 11 · 2013: 13 · 2012: 10
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- selective serotonin reuptake inhibitors, premenstrual syndrome, drug efficacy, pharmaceutical industry funding, adverse drug reactions, first-line therapy
- MeSH terms
- Female, Humans, Patient Dropouts, Premenstrual Syndrome, Randomized Controlled Trials as Topic, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
